SPRR2A

Across TCGA pan-cancer cohorts, SPRR2A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SPRR2A data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SPRR2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPRR2A expression acts as an unfavorable survival marker.

OV, STAD, and LUAD are the cancer types where SPRR2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.022	0.844	<.001	36	view →
STAD	OS	Median	All	0.022	0.731	<.001	18	view →
LUAD	DFS	Median	All	0.213	0.676	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SPRR2A–OV (OS)

Open the OV breakdown →